Literature DB >> 10957937

Recent advances in the diagnosis and treatment of pediatric inflammatory bowel disease.

E G Seidman1.   

Abstract

The diagnosis and management of inflammatory bowel disease (IBD) in children and adolescents is a challenge to patients, their families, and to the healthcare team. This review highlights recent advances in the epidemiology, diagnosis, and management of pediatric IBD. Among the most prominent advances are the new diagnostic serologic assays that can help screen for IBD in the absence of physical signs of disease and help discriminate between ulcerative and Crohn's colitis. Other tests have been identified as potential noninvasive markers of disease activity, including color Doppler abdominal ultrasound and sugar permeability tests. Recent advances in pharmacogenetics afford clinicians the ability to optimize and individualize therapy using azathioprine or 6-mercaptopurine. Finally, bone health has come forth as a major issue in the complete management of pediatric IBD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10957937     DOI: 10.1007/s11894-000-0068-y

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  13 in total

1.  Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease.

Authors:  F M Ruemmele; S R Targan; G Levy; M Dubinsky; J Braun; E G Seidman
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682

2.  Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.

Authors:  E V Loftus; M D Silverstein; W J Sandborn; W J Tremaine; W S Harmsen; A R Zinsmeister
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

3.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.

Authors:  M C Dubinsky; S Lamothe; H Y Yang; S R Targan; D Sinnett; Y Théorêt; E G Seidman
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

4.  Serologic testing for inflammatory bowel disease.

Authors:  E J Hoffenberg; S Fidanza; A Sauaia
Journal:  J Pediatr       Date:  1999-04       Impact factor: 4.406

5.  6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.

Authors:  C Cuffari; Y Théorêt; S Latour; G Seidman
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

6.  Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease.

Authors:  A Bousvaros; A Leichtner; D Zurakowski; J Kwon; T Law; K Keough; S Fishman
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

7.  Interpretation of bone mineral density values in pediatric Crohn's disease.

Authors:  D Herzog; N Bishop; F Glorieux; E G Seidman
Journal:  Inflamm Bowel Dis       Date:  1998-11       Impact factor: 5.325

Review 8.  Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions.

Authors:  L Lennard
Journal:  Ther Drug Monit       Date:  1998-10       Impact factor: 3.681

9.  Inflammatory bowel disease in African-American children living in Georgia.

Authors:  S O Ogunbi; J A Ransom; K Sullivan; B T Schoen; B D Gold
Journal:  J Pediatr       Date:  1998-07       Impact factor: 4.406

10.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.

Authors:  D C Pearson; G R May; G H Fick; L R Sutherland
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

View more
  2 in total

Review 1.  Pediatric inflammatory bowel disease.

Authors:  Karen-A Diefenbach; Christopher-K Breuer
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 2.  Pharmacogenetic tactics and strategies: implications for paediatrics.

Authors:  W W Weber
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.